Table 1.
Patient's clinical characteristics.
| Characteristics | Value |
|---|---|
| Gender | |
| Female | 9 |
| Male | 8 |
| Histology | |
| ARMS | 5 |
| ERMS | 3 |
| EWS | 5 |
| CIC-DUX | 1 |
| US | 1 |
| CCS | 1 |
| DSRCT | 1 |
| Mts at initial diagnosis | |
| Lung | 4 |
| Bone | 3 |
| BM | 2 |
| Peritoneal carcinomatosis | 1 |
| None | 9 |
| Response after 2 cycles | |
| CR | 1 |
| PR | 5 |
| PD | 4 |
| SD | 7 |
| Age at diagnosis | |
| ≥1 <10 | 3 |
| <1 ≥10 | 14 |
| Primary site | |
| Thorax | 2 |
| Extremity | 8 |
| HN PM | 3 |
| Axial | 1 |
| Pelvis | 2 |
| Unknown | 1 |
| Disease status | |
| Relapse | 10 |
| Refractory tumor | 1 |
| PD on 1st line therapy | 5 |
| PD on 2st line therapy | 1 |
| Outcome | |
| DOD | 12 |
| NED | 4 |
| AWD | 1 |
ARMS, alveolar rhabdomyosarcoma; ERMS, embryonal rhabdomyosarcoma; EWS, Ewing Sarcoma; CIC-DUX, CIC-DUX fusion transcript positive sarcoma; US, undifferentiated sarcoma; CCS, clear cell sarcoma; DSRCT, desmoplastic round cell tumor; HN PM, Head and neck parameningeal; Mts, metastasis; BM, bone-marrow; VIP, Vincristine/Irinotecan/Pazopanib; PD, progressive disease; CR, complete response; PR, partial response; SD, stable disease; DOD: died of disease; NED, no evidence of disease; AWD, alive with disease.